Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Nature communications
2025
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/41285854/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Immunological surveillance against cancer across mammals. Vincze, Orsolya Minias, Piotr Corthay, Alexandre Colchero, Fernando Lemaître, Jean-François Maille, Louise Malkócs, Tamás Hagemann, Justus Conde, Dalia A Pavard, Samuel Dujon, Antoine M Ujvari, Beata Thomas, Frédéric Boddy, Amy M Maley, Carlo C Chevallier, Damien Sepp, Tuul Pradeu, Thomas Giraudeau, Mathieu Animals Neoplasms Immunologic Surveillance Mammals Humans Antigen Presentation Species Specificity Genes, MHC Class I Histocompatibility Antigens Class I Contrary to expectations based on their higher cell numbers, larger and longer-lived species do not face dramatically increased risk of cancer. This strongly suggests that evolution has fashioned natural cancer resistance mechanisms, yet our knowledge remains limited on what these mechanisms might be. The cancer immunological surveillance hypothesis, proposed by Burnet and Thomas in the 1950s, highlights immunity as a key factor determining species-specific cancer resistance. Here we address the original, evolutionary interpretation of this hypothesis by investigating the relationship between cancer mortality risk and markers of efficient antigen presentation. Our results show that the expansion of the MHC class I gene complex, as well as increased selection for diversity at these genes is associated with sharply decreasing cancer mortality risk across mammals. This suggests that the efficient presentation of diverse peptides in somatic cells is important for cancer suppression across mammals, providing pioneering evidence that supports the cancer immunosurveillance hypothesis across species.